Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports

24.04.2024 | Structural Heart Disease (S Vakamudi, Section Editor)

Evidence-Based Update on Transcatheter Therapies for Pulmonary Embolism

verfasst von: Peter Monteleone, Akash Patel, Jonathan Paul

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pulmonary embolism (PE) remains a leading cause of cardiovascular morbidity and mortality. Multiple new therapies are in development and under study to improve our contemporary care of patients with PE. We review and compare here these novel therapeutics and technologies.

Recent Findings

Multiple novel therapeutic devices have been developed and are under active study. This work has advanced the care of patients with intermediate and high-risk PE.

Summary

Novel therapies are improving care of complex PE patients. These have inspired large multicenter international randomized controlled trials that are actively recruiting patients to advance the care of PE. These studies will work towards advancing guidelines for clinical care of patients with PE.
Literatur
1.
Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979–1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163:1711–7.CrossRefPubMed
2.
Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Am J Med. 2016;129(879):e19-25.
3.
Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. ClinicoEconomics and outcomes research : CEOR. 2015;7:451–62.CrossRefPubMed
4.
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–738.CrossRefPubMedPubMedCentral
5.
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019;54. The ESC guidelines present a commonly used algorithm for risk stratification of patients with PE. This contemporary stratification system is frequently implemented in current practice and decision making in the care of PE patients.
6.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52.CrossRefPubMed
7.
Frémont B, Pacouret G, Jacobi D, Puglisi R, Charbonnier B, de Labriolle A. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism: results from a monocenter registry of 1,416 patients. Chest. 2008;133:358–62.CrossRefPubMed
8.
van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology. 2005;235:798–803.CrossRefPubMed
9.
Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med. 2006;166:2151–6.CrossRefPubMed
10.
Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113:577–82.CrossRefPubMed
11.
• Natanzon SS, Fardman A, Chernomordik F, et al. PESI score for predicting clinical outcomes in PE patients with right ventricular involvement. Heart and vessels. 2022;37:489–95. This work presents the PESI risk score for risk stratifying patients with pulmonary embolism to guide decision making in therapy.CrossRefPubMed
12.
13.
Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA. 1970;214:2163–72.
14.
Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11.CrossRefPubMed
15.
Konstantinides SV, Vicaut E, Danays T, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69:1536–44.CrossRefPubMed
16.
Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36:605–14.CrossRefPubMed
17.
Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Günther RW. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol. 2000;36:375–80.CrossRefPubMed
18.
Bonvini RF, Righini M, Roffi M. Angiojet rheolytic thrombectomy in massive pulmonary embolism: locally efficacious but systemically deleterious? J Vasc Interv Radiol. 2010;21:1774–6; author reply 6-7.CrossRefPubMed
19.
Tapson VF, Gurbel PA, Witty LA, Pieper KS, Stack RS. Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy Chest. 1994;106:1558–62.PubMed
20.
Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood. 1993;81:2636–43.CrossRefPubMed
21.
Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol. 1995;21:419–24.CrossRefPubMed
22.
Owens CA. Ultrasound-enhanced thrombolysis: EKOS EndoWave infusion catheter system. Semin Interv Radiol. 2008;25:37–41.CrossRef
23.
Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129:479–86.CrossRefPubMed
24.
Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv. 2015;8:1382–92.CrossRefPubMed
25.
Tapson VF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv. 2018;11:1401–10.CrossRefPubMed
26.
27.
Sterling K. KNOCOUT PE: retrospective and prospective international EKoSoNic registry of the treatment and clinical outcomes of patients with pulmonary embolism. Vascular InterVentional Advances Conference; 2021; Las Vegas, NV.
28.
Avgerinos ED, Jaber W, Lacomis J, et al. Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: the SUNSET sPE trial. JACC Cardiovasc Interv. 2021;14:1364–73.CrossRefPubMedPubMedCentral
29.
Klok FA, Piazza G, Sharp ASP, Ní Ainle F, Jaff MR, Chauhan N, et al. Ultrasound-facilitated,catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. Am Heart J. 2022;251:43–53. https://​doi.​org/​10.​1016/​j.​ahj.​2022.​05.​011. Epub 2022 May 16. PMID: 35588898.
30.
Sista AK, Bhatheja R, Rali P, et al. First-in-human study to assess the safety and feasibility of the bashir endovascular catheter for the treatment of acute intermediate-risk pulmonary embolism. Circ Cardiovasc Interv. 2021;14: e009611.CrossRefPubMed
31.
Bashir R, Foster M, Iskander A, et al. Pharmacomechanical catheter-directed thrombolysis with the bashir endovascular catheter for acute pulmonary embolism: the RESCUE study. JACC Cardiovasc Interv. 2022;15:2427–36.CrossRefPubMed
32.
Tu T, Toma C, Tapson VF, et al. A prospective, single-arm, multicenter trial of catheter-directed mechanical thrombectomy for intermediate-risk acute pulmonary embolism: the FLARE study. JACC Cardiovasc Interv. 2019;12:859–69.CrossRefPubMed
33.
Toma C, Bunte MC, Cho KH, et al. Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: interim results of the FLASH registry. Catheter Cardiovasc Interv: J Soc Cardiovasc Angiogr Interv. 2022;99:1345–55.CrossRef
34.
Silver MJ, Gibson CM, Giri J, Khandhar S, Jaber W, Toma C, et al. Outcomes in High-Risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy or Other Contemporary Therapies: Results From the FLAME Study. Circ Cardiovasc Interv. 2023:16(10):e013406. https://​doi.​org/​10.​1161/​CIRCINTERVENTION​S.​123.​013406. Epub 2023. PMID: 37847768; PMCID: PMC10573120.
35.
Saxon RR, Benenati JF, Teigen C, Adams GL, Sewall LE. Utility of a power aspiration-based extraction technique as an initial and secondary approach in the treatment of peripheral arterial thromboembolism: results of the multicenter PRISM trial. J Vasc Interv Radiol. 2018;29:92–100.CrossRefPubMed
36.
Sista AK, Horowitz JM, Tapson VF, et al. Indigo aspiration system for treatment of pulmonary embolism: results of the EXTRACT-PE trial. JACC Cardiovasc Interv. 2021;14:319–29.CrossRefPubMed
37.
Robertson B, Neville E, Muck A, et al. Technical success and short-term results from mechanical thrombectomy for lower extremity iliofemoral deep vein thrombosis using a computer aided mechanical aspiration thrombectomy device. J Vasc Surg Venous Lymphat Disord. 2022;10:594–601.CrossRefPubMed
38.
Enezate T, Alkhatib D, Raja J, Chinta V, Patel M, Omran J. AngioVac for minimally invasive removal of intravascular and intracardiac masses: a systematic review. Curr Cardiol Rep. 2022;24:377–82.CrossRefPubMed
39.
40.
Ain DL, Albaghdadi M, Giri J, et al. Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: two eras at an urban tertiary care hospital. Vascular medicine (London, England). 2018;23:60–4.CrossRefPubMed
41.
Karami M, Mandigers L, Miranda DDR, et al. Survival of patients with acute pulmonary embolism treated with venoarterial extracorporeal membrane oxygenation: a systematic review and meta-analysis. J Crit Care. 2021;64:245–54.CrossRefPubMed
42.
Zuin M, Rigatelli G, Daggubati R, Nguyen T, Roncon L. Impella RP in hemodynamically unstable patients with acute pulmonary embolism. J Artif Organs: J Japanese Soc Artif Organs. 2020;23:105–12.CrossRef
Metadaten
Titel
Evidence-Based Update on Transcatheter Therapies for Pulmonary Embolism
verfasst von
Peter Monteleone
Akash Patel
Jonathan Paul
Publikationsdatum
24.04.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02060-3

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise